相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
Wolfgang Wick et al.
CLINICAL CANCER RESEARCH (2016)
Large-scale assessment of the gliomasphere model system
Dan R. Laks et al.
NEURO-ONCOLOGY (2016)
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2015)
The mTOR signaling pathway as a treatment target for intracranial neoplasms
Doreen Pachow et al.
NEURO-ONCOLOGY (2015)
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K
Daniel J. Ma et al.
NEURO-ONCOLOGY (2015)
The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells
Jenna Kahn et al.
NEURO-ONCOLOGY (2014)
Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
Brett E. Johnson et al.
SCIENCE (2014)
Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma
H. -S. Shiah et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Prakash Chinnaiyan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study
Warren P. Mason et al.
INVESTIGATIONAL NEW DRUGS (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
NORTH CENTRAL CANCER TREATMENT GROUP PHASE I TRIAL N057K OF EVEROLIMUS (RAD001) AND TEMOZOLOMIDE IN COMBINATION WITH RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
Jann N. Sarkaria et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
VALIDATION AND SIMPLIFICATION OF THE RADIATION THERAPY ONCOLOGY GROUP RECURSIVE PARTITIONING ANALYSIS CLASSIFICATION FOR GLIOBLASTOMA
Jing Li et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Clinical trial end points for high-grade glioma: the evolving landscape
David A. Reardon et al.
NEURO-ONCOLOGY (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks
Jann N. Sarkaria et al.
CLINICAL CANCER RESEARCH (2010)
Everolimus: efficacy and safety in cardiac transplantation
S. Allan Schaffer et al.
EXPERT OPINION ON DRUG SAFETY (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis.
Darcy A. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
Chiaki Tanaka et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Malignant gliomas in adults
Patrick Y. Wen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-Deficient glioblastoma
Tim F. Cloughesy et al.
PLOS MEDICINE (2008)
IKKβ suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway
Dung-Fang Lee et al.
CELL (2007)
Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells
Carolyn Cao et al.
CANCER RESEARCH (2006)
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-Deficient and PTEN-intact glioblastoma cells
Maria Y. Wang et al.
CANCER RESEARCH (2006)
Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer
Jeffrey M. Albert et al.
MOLECULAR CANCER THERAPEUTICS (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Enhanced radiation damage of tumor vasculature by mTOR inhibitors
ET Shinohara et al.
ONCOGENE (2005)
分享论文
